BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 20872906)

  • 1. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study.
    Chiu HF; Huang YW; Chang CC; Yang CY
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1131-6. PubMed ID: 20872906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.
    Kaye JA; Jick H
    Pharmacotherapy; 2008 Aug; 28(8):951-9. PubMed ID: 18657011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton pump inhibitor use and the antifracture efficacy of alendronate.
    Abrahamsen B; Eiken P; Eastell R
    Arch Intern Med; 2011 Jun; 171(11):998-1004. PubMed ID: 21321287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton pump inhibitors and fractures? Beware long-term use.
    Prescrire Int; 2009 Oct; 18(103):216. PubMed ID: 19885973
    [No Abstract]   [Full Text] [Related]  

  • 5. Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm.
    Moayyedi P; Cranney A
    Am J Gastroenterol; 2008 Oct; 103(10):2428-31. PubMed ID: 18855852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region.
    Reyes C; Formiga F; Coderch M; Hoyo J; Ferriz G; Casanovas J; Monteserín R; Brotons C; Rojas M; Moral I
    Bone; 2013 Feb; 52(2):557-61. PubMed ID: 23023097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
    Lin SM; Yang SH; Liang CC; Huang HK
    Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton pump-inhibiting drugs, calcium homeostasis, and bone health.
    Wright MJ; Proctor DD; Insogna KL; Kerstetter JE
    Nutr Rev; 2008 Feb; 66(2):103-8. PubMed ID: 18254877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton pump inhibitors and bone fractures?
    Laine L
    Am J Gastroenterol; 2009 Mar; 104 Suppl 2():S21-6. PubMed ID: 19262543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.
    Lee J; Youn K; Choi NK; Lee JH; Kang D; Song HJ; Park BJ
    J Gastroenterol; 2013 Sep; 48(9):1016-22. PubMed ID: 23307040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opportunities to decrease inappropriate uses of proton pump inhibitors: Comment on "Proton pump inhibitor use and the antifracture efficacy of alendronate".
    Katz MH
    Arch Intern Med; 2011 Jun; 171(11):1004-5. PubMed ID: 21321289
    [No Abstract]   [Full Text] [Related]  

  • 12. Exposure to antiepileptic drugs and the risk of hip fracture: a case-control study.
    Tsiropoulos I; Andersen M; Nymark T; Lauritsen J; Gaist D; Hallas J
    Epilepsia; 2008 Dec; 49(12):2092-9. PubMed ID: 18479399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice.
    McGowan B; Bennett K; Barry M
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):763-9. PubMed ID: 20582909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inverse association between duration of use of acid-suppressive medications and fracture risk.
    de Vries F
    Arch Intern Med; 2011 Jun; 171(11):1044; author reply 1044. PubMed ID: 21670381
    [No Abstract]   [Full Text] [Related]  

  • 15. Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting.
    Cea Soriano L; Ruigómez A; Johansson S; García Rodríguez LA
    Pharmacotherapy; 2014 Jun; 34(6):570-81. PubMed ID: 24634193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton-pump inhibitor use and hip fractures in men: a population-based case-control study.
    Adams AL; Black MH; Zhang JL; Shi JM; Jacobsen SJ
    Ann Epidemiol; 2014 Apr; 24(4):286-90. PubMed ID: 24507954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of proton pump-inhibiting drugs on mineral metabolism.
    Insogna KL
    Am J Gastroenterol; 2009 Mar; 104 Suppl 2():S2-4. PubMed ID: 19262542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis.
    Ye X; Liu H; Wu C; Qin Y; Zang J; Gao Q; Zhang X; He J
    Eur J Gastroenterol Hepatol; 2011 Sep; 23(9):794-800. PubMed ID: 21701389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study.
    Pouwels S; Lalmohamed A; Souverein P; Cooper C; Veldt BJ; Leufkens HG; de Boer A; van Staa T; de Vries F
    Osteoporos Int; 2011 Mar; 22(3):903-10. PubMed ID: 20585937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton pump inhibitors and the risk of colorectal cancer.
    van Soest EM; van Rossum LG; Dieleman JP; van Oijen MG; Siersema PD; Sturkenboom MC; Kuipers EJ
    Am J Gastroenterol; 2008 Apr; 103(4):966-73. PubMed ID: 18070237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.